Calcutta HC: Award May Be Set Aside if Tribunal Rewrites Contract or Ignores Key Clauses  ||  Delhi HC Suspends Kuldeep Singh Sengar’s Life Term, Holding Section 5(C) of POCSO Not Made Out  ||  Calcutta High Court: Arbitration Clause in an Expired Lease Cannot be Invoked For a Fresh Lease  ||  Delhi High Court: 120-Day Timeline under Section 132B Of Income Tax Act is Not Mandatory  ||  NCLAT Reaffirms That Borrower's Debt Acknowledgment Also Extends Limitation Period for Guarantors  ||  NCLAT: Oppression & Mismanagement Petition Cannot Be Filed Without Company Membership on Filing Date  ||  Supreme Court Quashes Rajasthan Village Renaming, Says Government Must Follow its Own Policy  ||  NCLAT: NCLT Can Order Forensic Audit on its Own, No Separate Application Required  ||  NCLAT Reiterates That IBC Cannot be Invoked as a Recovery Tool for Contractual Disputes  ||  Delhi HC: DRI or Central Revenues Control Lab Presence in Delhi Alone Does Not Confer Jurisdiction    

Competition Commission of India Levies Rs 74 Cr Fine on Himalaya Drug and Three Others - (05 Jun 2019)

MRTP/ COMPETITION LAWS

Competition Commission of India has imposed a total fine of over Rs 74 crore on Himalaya Drug Company and Intas Pharmaceuticals along with its senior officials as well as two Madhya Pradesh-based drug groupings namely Madhya Pradesh Chemists and Druggist Association and Indore Chemists Association for indulging in anti-competitive trade practices.

Tags : COMPETITION COMMISSION OF INDIA   HIMALAYA DRUG  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved